A federal jury in Boston has delivered a historic $885 million antitrust verdict against Takeda Pharmaceutical, marking the first trial defeat for a drugmaker in a "pay-for-delay" class-action lawsuit since a pivotal 2013 U.S. Supreme Court decision. The decision directly impacts the financial risks of pharmaceutical patent litigation, as federal antitrust law allows the initial $885 million award to be automatically tripled, elevating Takeda’s potential liability to more than $2.6 billion. The jury determined that Takeda engaged in an anticompetitive scheme to intentionally stall market entry for a generic version of the chronic constipation drug Amitiza, awarding the damages to a class of affected pharmacies, insurers, and retailers, Reuters reported.
The litigation originated from a 2012 patent infringement lawsuit filed by Takeda and its partner, Sucampo, after Par Pharmaceutical sought FDA approval for a generic alternative. Plaintiffs established at trial that a subsequent 2014 settlement agreement included a $210 million payoff that successfully delayed generic competition for six years until 2021, when Par finally launched an authorized generic under a profit-sharing arrangement. Plaintiffs argued this specific structure unlawfully extended market exclusivity and inflated procurement costs for commercial buyers, while Takeda maintained that the resolution was a lawful, pro-competitive settlement of legitimate patent claims.
The rare plaintiff victory at trial establishes a potent precedent that alters the defense landscape for brand-name manufacturers utilizing reverse-payment agreements to settle generic challenges. While industry peers like AbbVie and Teva have faced identical scrutiny, Takeda represents the first to lose before a jury under the current legal framework. Takeda has denied all wrongdoing and announced plans to challenge the verdict through post-trial appeals, while plaintiffs' counsel highlighted the broader market impact, stating that the jury "understood that paying off a competitor has real consequences on competition.”
